Sex-specific analysis of renal cell carcinoma histology and survival in Japan: A population-based study 2004 to 2016

Masayoshi Zaitsu1,2 | Satoshi Toyokawa1 | Takumi Takeuchi3 | Yasuki Kobayashi1 | Ichiro Kawachi2

1Department of Public Health, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
2Department of Social and Behavioral Sciences, Harvard T.H. Chan School of Public Health, Boston, Massachusetts
3Department of Urology, Kanto Rosai Hospital, Kawasaki, Japan

Correspondence
Masayoshi Zaitsu, MD, PhD, Department of Public Health, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan; or Department of Social and Behavioral Sciences, Harvard T.H. Chan School of Public Health, 677 Huntington Avenue, 7th Floor, Boston, Massachusetts 02115, USA.
Email: m-zaitsu@m.u-tokyo.ac.jp; mzaitsu@hsph.harvard.edu

Funding information
Japan Society for the Promotion of Science, Grant/Award Number: JSPS KAKENHI JP18K17351; Ministry of Health, Labour and Welfare, Grant/Award Number: Industrial Disease Clinical Research Grants 170201

Abstract
Background and aims: In Western countries, sex differences in renal cell carcinoma (RCC) histology and survival have been previously described: compared with men, clear cell subtype is more common but overall prognosis is better among women. The goal of the present study was to examine sex differences in RCC histology and survival in Japan, using a large-scale population-based data set.

Methods: With the use of a population-based cancer registry in Japan (2004-2016), patients with primary RCC were followed for 5 years (median follow-up time 2.1 years). We distinguished histological subtypes of clear cell, papillary, and chromophobe from "others" subtype. Sex-specific prevalence ratio (PR) for each histological subtype was estimated by Poisson regression with robust variance, adjusted for age and year of diagnosis. Sex-specific survival rates were estimated by Cox proportional hazard regression, adjusted for age, year of diagnosis, histological subtypes, and other prognostic variables, with multiple imputation.

Results: The prevalence of clear cell and "others" subtypes was similar between men and women among all the 5265 study subjects during the 12 years of study (clear cell, male 88.6% vs female 87.1%; "others", male 5.3% vs female 5.3%). However, papillary subtype was less common among women than men (male 4.6% vs female 2.8%; PR = 0.63; 95% CI, 0.45-0.88), while chromophobe subtype was more common among women (male 1.6% vs female 4.8%; PR = 3.18; 95% CI, 2.26-4.47). Although "others" subtype (but not papillary/chromophobe subtypes) independently predicted prognosis (HR = 1.74; 95% CI, 1.32-2.30), no sex differences were observed in RCC survival.

Conclusion: We did not observe a statistically significant difference in the prevalence of clear cell subtype between men and women in Japan, which differs from the pattern previously described in Western countries. Sex differences in RCC histology may not affect RCC survival in this population.
1 | INTRODUCTION

Renal cell carcinoma (RCC) ranks as the sixth most common type of cancer in men and 10th among women, worldwide, accounting for 5% and 3% of overall cancer incidence, respectively.¹ The incidence rate for RCC in Asian countries, including Japan, is roughly one-third compared with that in Western countries,¹ and the lower RCC incidence in Japan may be attributable to the lower prevalence of obesity (a prominent risk for RCC²) in that country compared with the Western settings. However, the incidence has been rising in recent years in Japan.¹-³ Advanced imaging modalities, together with changes in lifestyle and behavioral risks (such as smoking, obesity, hypertension, and occupational stress), may underlie the increase in incidence.³⁻⁵

Prognostic differences according to histological subtypes are well described. In the United States (USA), studies using the Surveillance, Epidemiology, and End Results (SEER) database suggest that the most common histological subtype is the clear cell subtype (approximately 80%-90%), followed by the papillary (approximately 4%-13%) and chromophobe (approximately 2%-5%) subtypes.⁶⁻⁸ Compared with the clear cell subtype, patients with papillary and chromophobe subtypes tend to have better prognosis (hazard ratio [HR] approximately 0.67-0.98), but patients with other rare histological subtypes (eg, collecting duct and sarcomatoid differentiation) tend to have a poorer prognosis (HR approximately 1.81-2.21).⁸ Previous single-center studies in the United States are consistent with this pattern.⁹⁻¹⁰

More recently, studies in Western settings have reported sex differences in RCC histology and survival.¹¹⁻¹⁴ The clear cell subtype is likely more prevalent among women compared with men (88% vs 85%).¹¹ In addition, among all incident RCC, the papillary subtype tends to be approximately 0.5 to 0.6 times less prevalent, but the chromophobe subtype tends to be approximately 1.6 to 2.3 times more prevalent among women compared with men.¹²⁻¹³ Sex differences in RCC histology, particularly in the clear cell subtype, may be partly attributed to lifestyle and behavioral factors such as obesity,¹⁵ which is generally more prevalent in women than men across most countries,¹⁶ and smoking.¹⁷ However, compared with men, RCC prognosis has been reported to be better among women (HR 0.92) even though the clear cell subtype, which has a more unfavorable prognosis, was more prevalent among women.¹¹ Other female clinicopathological features (lower pathological grade, earlier stage of detection, and higher prevalence of chromophobe subtype) linked to favorable prognosis may underlie these paradoxical sex differences in RCC histology and survival.⁸⁻¹¹⁻¹³

Reports of sex differences in RCC histology and survival remain scarce in Asian settings. For example, in Japan, although the Japanese Urological Association has reported descriptive statistics of RCC histology and 5-year overall survival with multicenter data (but not population-based data),¹⁸ sex differences in RCC histology and survival have not been previously assessed. One study in South Korea, with 1508 RCC patients, examined sex differences and reported lower prevalence of clear cell subtypes among women compared with men (female 72% vs male 84%) but a nonsignificant sex difference in survival, which contradicts the Western pattern.¹⁹ However, this was a relatively small, single-center study, and it was not population based.

Accordingly, the goal of the present study was to examine sex differences in RCC histology and survival in Japan, using a large-scale population-based data set with over 5000 RCC patients. We sought to examine whether sex differences exist in RCC histology and whether there are overall survival differences by sex and by histological subtypes in Japan. Also, we sought to determine whether a sex difference in survival, if there is one, persists even after controlling for histological subtypes and other potential prognostic factors such as pathological grade, tumor stage, treatment, socioeconomic status (SES), and smoking habits.

2 | MATERIALS AND METHODS

2.1 | Data setting and study subjects

A large, population-based data set (2004-2016) of Kanagawa Cancer Registry (KCR), a survey of over nine million people in Kanagawa prefecture that covers approximately 7% of the Japanese population, was used for analysis. Details of the study database have been previously described elsewhere.²⁰,²¹ Briefly, Kanagawa Prefecture, a metropolitan prefecture located next to Tokyo, is the second largest prefecture in Japan, and KCR is one of the largest local cancer registries in Japan. Well-trained tumor registrars certified by the training program of the Japanese Association of Cancer Registries, whose program is accredited by SEER, are responsible for data collection. The data included basic information (sex, age, date of diagnosis, and date of death/last follow-up) and clinical information (pathology, stage, and treatment). Uniquely, KCR collected information on occupation and smoking behaviors, if available, during the study period (approximately 10% of the registered cases); however, these data are no longer obtained since 2016 because of a change of data management practice. KCR automatically updates dates of death/last follow-up with population registers and death certificates, and previous diagnosis codes, as well as pathological codes, are updated to be consistent with changes in coding practice. We obtained a deidentified data set under the research agreement between the authors and KCR, and the research ethics committee of The University of Tokyo, Tokyo (Protocol Number 3891-4), approved the study.

KEYWORDS
kidney cancer, pathology, population-based, sex difference, survival
We included all 7525 RCC patients registered in the KCR (a) who were diagnosed with RCC (C64 in International Classification of Diseases, 10th revision) between 2004 and 2014, (b) aged 20 and above, and (c) who had complete observation duration. We excluded those who had missing data for pathological type.

2.2 Histological subtype and 5-year overall survival

Using pathology codes (identified by International Classification of Disease for Oncology, Third edition [ICD-O-3] pathology codes), we distinguished the histological subtypes of clear cell (ICD-O-3 codes of 8310, 8312, 8316, and 8320), papillary (ICD-O-3 code of 8260), and chromophobe (ICD-O-3 codes of 8270 and 8317) from “others” subtype (eg, collecting duct and sarcomatoid differentiation), according to previous SEER studies.6,8,22 The 5-year overall survival was defined by the right-censored, observation duration (person-years) from the date of initial diagnosis to the date of death/last follow-up (median follow-up time, 2.1 years).

2.3 Covariates

The age (1-year age category) and year of diagnosis (calendar year) were adjusted as continuous variables across all statistical models. To control for secular changes in clinicopathological diagnosis and treatment regimens, including surgery and systemic therapies, over time,

| TABLE 1 | Characteristics of renal cell carcinoma patients in Kanagawa Cancer Registry |
|----------|--------------------------------------------------------------------------------|
| Characteristics | Mean (SD) or Number (%) | Multiple Imputation |
|               | Crude | All n = 5265 | Men n = 3820 | Women n = 1445 | P<sup>bc</sup> | All n = 5265 | Men n = 3820 | Women n = 1445 |
| Basic characteristics |               |               |               |               |               |               |
| **Histology**<sup>cd</sup> |               |               |               |               |               |               |
| Clear cell | 4642 (88.2%) | 3383 (88.6%) | 1259 (87.1%) | .15 | 88.2% | 88.6% | 87.1% |
| Papillary | 217 (4.1%) | 176 (4.6%) | 41 (2.8%) | .004 | 4.1% | 4.6% | 2.8% |
| Chromophobe | 129 (2.5%) | 60 (1.6%) | 69 (4.8%) | <.001 | 2.5% | 1.6% | 4.8% |
| Others | 277 (5.3%) | 201 (5.3%) | 76 (5.3%) | >.99 | 5.3% | 5.3% | 5.3% |
| Age, y | 64 (12) | 64 (12) | 65 (12) | <.001 | 64 (12) | 64 (12) | 65 (12) |
| Year of diagnosis | 2009 (3) | 2009 (3) | 2009 (3) | .23 | 2009 (3) | 2009 (3) | 2009 (3) |
| **Other backgrounds**<sup>e</sup> |               |               |               |               |               |               |
| Pathological grade | n = 3,368 | n = 2,424 | n = 944 |               |               |               |
| High grade | 355 (10.5%) | 257 (10.6%) | 98 (10.4%) | .85 | 12.6% | 12.5% | 12.7% |
| Stage | n = 3791 | n = 2753 | n = 1038 |               |               |               |
| Late stage | 983 (25.9%) | 724 (26.3%) | 259 (25.0%) | .40 | 32.9% | 33.1% | 32.3% |
| Treatment | n = 4922 | n = 3562 | n = 1360 |               |               |               |
| Surgery | 4656 (94.6%) | 3368 (94.6%) | 1288 (94.7%) | .83 | 94.2% | 94.1% | 94.2% |
| SES | n = 359 | n = 316 | n = 43 |               |               |               |
| High-SES | 73 (20.3%) | 62 (19.6%) | 11 (25.6%) | .36 | 27.5% | 27.7% | 27.1% |
| Smoking | n = 1603 | n = 1162 | n = 441 |               |               |               |
| Ever smoker | 789 (49.2%) | 712 (61.3%) | 77 (17.5%) | <.001 | 49.6% | 61.8% | 17.4% |
| 5-y overall survival, % |               |               |               |               |               |
| Overall | 72.0% | 72.0% | 71.9% | .95 | 72.0% | 72.0% | 71.9% |
| Clear cell | 74.2% | 74.0% | 74.8% | .61 | 74.2% | 74.0% | 74.8% |
| Papillary | 75.4% | 76.7% | 70.1% | .45 | 75.4% | 76.7% | 70.1% |
| Chromophobe | 89.0% | 91.8% | 86.1% | .48 | 89.0% | 91.8% | 86.1% |
| Others | 30.3% | 33.3% | 22.6% | .06 | 30.3% | 33.3% | 22.6% |

Abbreviation: SES, socioeconomic status.

<sup>a</sup>Percentage may not total 100 because of rounding and multiple imputation.

<sup>b</sup>P values are for chi-squared test or t test.

<sup>c</sup>Data were estimated with 20 imputed data sets. The number of missing data was, respectively, as follows: pathological grade (1897, 36.0%), stage (1474, 28.0%), surgery (343, 6.5%), SES (4906, 93.2%), and smoking habits (3662, 69.6%).

<sup>d</sup>The distribution of all histological subtypes combined differed between men and women (chi-squared test, P < .001).

<sup>e</sup>Missing data are included.
we adjusted for year of diagnosis. Additionally, clinicopathological variables were included in survival analyses as potential mediating variables, ie, these variables do not confound the association between sex and RCC survival, but rather, they may help to explain the observed differences. Our clinicopathological variables of interest included the following: WHO pathological grade (grades 3 or 4 [high-grade] vs grades 1 or 2 [low-grade]), the Union for International Cancer Control TNM stage (stages III and IV [late stage] vs stages I and II [early stage]), and any performed surgeries including radical/partial nephrectomy (yes/no), as well as SES (high SES [with the longest-held occupational class of managerial or professional workers] vs low SES) and smoking habits (never/ever).

2.4 Statistical analysis

The background characteristics between men and women were compared by t test or chi-squared test. The 5-year overall survival rates were estimated with Kaplan-Meier curves and compared by log-rank test. Except for basic characteristics (age, sex, year of diagnosis, and survival time) and histological subtypes, records included missing data on mediating factors: pathological grade (1897, 36.0%), stage (1474, 28.0%), surgery (343, 6.5%), SES (4906, 93.2%), and smoking habits (3662, 69.6%). Excluding patients with missing data may lead to biased inference; therefore, we conducted multiple imputation for missing data among the 5265 study subjects with all variables used for analysis, and 20 imputed data sets were generated by the Multiple Imputation by Chained Equations method (Table 1).

In our main analytic model for the sex difference in histology (model 1), prevalence ratio (PR) and 95% confidence interval (CI) for each histological subtype were estimated by Poisson regression with robust variance, adjusted for age and year of diagnosis. Male patients served as the reference group for all analyses. In a Poisson regression with multiple imputation, we further controlled for pathological grade and stage (model 2) and SES and smoking habits (model 3) as potential mediating variables. In prior analyses, according to the methodology used in previous studies (multinomial logistic regression model), 2.3,9 we estimated multinomial odds ratios (in other word, relative risk ratios) for each type of RCC against a specific RCC (ie, clear cell).

For histological subtypes, the distribution differed between men and women (Table 1). The prevalence of clear cell and "others" subtype was similar between men and women (clear cell, male 88.6%, female 87.1%; "others," male 5.3%, female 5.3%). However, the papillary subtype was less prevalent among women compared with men (male 4.6%, female 2.8%, P = .004, chi-squared test), while chromophobe subtype was more prevalent among women compared with men (male 1.6%, female 4.8%, P < .001, chi-squared test; Table 1). Except for histological subtypes, age, and smoking habits, background characteristics and 5-year overall survival rates did not show a statistically significant difference between men and women (Table 1).

In Poisson regression with robust variance, although the maximally adjusted PR of clear cell subtype showed a marginally lower prevalence in women (PR = 0.97, 95% CI, 0.96-0.996, model 3), the PRs of clear cell subtype in model 1 and model 2 did not significantly differ between men and women (Table 2). Papillary subtype was less prevalent in women compared with men (model 1, Table 2): PR = 0.63 (95% CI, 0.45-0.88). By contrast, chromophobe subtype was more prevalent in women (PR = 3.18; 95% CI, 2.26-4.47). Even in the maximally adjusted model, papillary subtypes remained less prevalent, but chromophobe subtypes remained more prevalent in women compared with men (model 3, Table 2). The PR of the "others" subtype did not differ between men and women (Table 2).

In survival analyses, although the 5-year overall survival rate was 72% in this population, patients with the "others" subtype had a poor prognosis (30.3%, Table 1). However, no statistically significant differences were observed between men and women, even after stratifying by histological subtypes (Table 1). In the Cox regression analysis,
although the chromophobe subtype predicted a better prognosis and the "others" subtype predicted a poor prognosis, only the "others" subtype predicted prognosis in the maximally adjusted model (HR 1.74; 95% CI 1.32-2.30, model 4, Table 3). However, we did not observe a statistically significant difference in the 5-year overall survival between men and women in model 1 through model 4 (Table 3).

In sensitivity analyses, the observed patterns were almost identical to the main results (Table 4). The multinomial odds ratios of women for the papillary, chromophobe, and "others" subtypes were, respectively, 0.64 (95% CI, 0.45-0.91), 3.25 (95% CI, 2.28-4.64), and 0.99 (95% CI, 0.75-1.30).

### DISCUSSION

As far as we are aware, this is the first analysis of sex differences in histology and survival in RCC patients in Japan. Compared with men, although women did not have a significantly different prevalence for clear cell and "others" subtypes, women had different prevalence for papillary and chromophobe subtypes (0.6 times lower prevalence for papillary subtype and 3.2 times higher prevalence for chromophobe subtype). Even after controlling for potential mediating factors, the sex difference for these histological subtypes persisted. However, the survival was similar between men and women, even after accounting

### TABLE 2

| Characteristics | Prevalence Ratio (95% Confidence Interval), n = 5265 |
|-----------------|---------------------------------------------------|
| **Clear cell**  |                                                   |
| Women           | 0.98 (0.96, 1.01)                                 |
| Age, continuous | 1.00 (1.00, 1.00)                                 |
| Year of diagnosis, continuous | 0.99 (0.99, 0.99) <.001 |
| High grade      | 0.74 (0.69, 0.80)                                 |
| Late stage      | 0.98 (0.94, 1.02)                                 |
| High SES        | 1.00 (0.94, 1.07)                                 |
| Ever smoker     | 0.97 (0.93, 1.01)                                 |
| **Papillary**   |                                                   |
| Women           | 0.63 (0.45, 0.88)                                 |
| Age, continuous | 1.00 (0.99, 1.01)                                 |
| Year of diagnosis, continuous | 1.18 (1.12, 1.23) <.001 |
| High grade      | 2.04 (1.38, 3.03)                                 |
| Late stage      | 0.65 (0.45, 0.95)                                 |
| High SES        | 0.98 (0.63, 1.52)                                 |
| Ever smoker     | 1.19 (0.83, 1.72)                                 |
| **Chromophobe** |                                                   |
| Women           | 3.18 (2.26, 4.47)                                 |
| Age, continuous | 0.98 (0.97, 1.00)                                 |
| Year of diagnosis, continuous | 1.18 (1.11, 1.27) <.001 |
| High grade      | 1.35 (0.71, 2.55)                                 |
| Late stage      | 0.39 (0.21, 0.74)                                 |
| High SES        | 1.03 (0.48, 2.23)                                 |
| Ever smoker     | 1.11 (0.69, 1.81)                                 |
| **Others**      |                                                   |
| Women           | 0.97 (0.75, 1.26)                                 |
| Age, continuous | 1.02 (1.00, 1.03)                                 |
| Year of diagnosis, continuous | 0.99 (0.95, 1.03) .59 |
| High grade      | 6.21 (4.04, 9.53)                                 |
| Late stage      | 2.55 (1.38, 4.73)                                 |
| High SES        | 0.95 (0.43, 2.13)                                 |
| Ever smoker     | 1.47 (0.86, 2.51)                                 |

**Abbreviation:** SES, socioeconomic status.

*a*Data were estimated with 20 imputed data sets.
for survival differences by histological subtypes (eg, RCC patients with "others" subtype had 1.7 times poorer survival), as well as other potential prognostic factors.

Differences in female lifestyle and behavioral risks (obesity and smoking) between Western countries and Japan may underlie our observed sex difference in RCC histology of the clear cell subtype,15,17 which differs from the pattern seen in Western countries.8,13,22 Although the prevalence of the clear cell subtype varies across populations and regions, studies in the United States and Europe consistently suggest a higher prevalence of the clear cell subtype among women, by approximately 2% to 7%.8,11-14,22 However, the prevalence of the clear cell subtype was not higher among women compared with men in our study population in Japan, which partly coincides with the result from South Korea.19 Studies imply potential pathways of group-based differences in the risk for the clear cell subtype via obesity, smoking, hypertension, and end-stage renal disease in combination with genetic factors (APOL1 gene).1,12,13,15,17,24 Since obesity and smoking habits are far less common among Asian women compared with their counterparts in Western countries,16,25 the flat "gradient" of sex difference in the clear cell subtype seems plausible as an explanation for the discrepancy between the results obtained from Western and Asian countries.

### TABLE 3 Hazard ratios for 5-year overall survival estimated by Cox proportional hazard model

| Characteristics          | Hazard Ratio (95% Confidence Interval), n = 5265 |
|-------------------------|---------------------------------------------|
|                         | Model 1                                      | Model 2                                      | Model 31                                     | Model 41                                     | P       |
| Women                   | 0.95 (0.82, 1.08)                           | 0.99 (0.86, 1.13)                           | 0.98 (0.84, 1.15)                           | 1.13 (0.94, 1.37)                           | .42     |
| Age                     | 1.04 (1.03, 1.04)                           | 1.03 (1.03, 1.04)                           | 1.03 (1.02, 1.04)                           | 1.03 (1.02, 1.03)                           | <.001   |
| Year of diagnosis       | 1.07 (1.04, 1.10)                           | 1.08 (1.05, 1.10)                           | 1.11 (1.07, 1.16)                           | 1.13 (1.08, 1.17)                           | <.001   |
| Clear cell subtype      |                                             |                                             |                                             |                                             |        |
| Papillary               | 0.84 (0.59, 1.19)                           | 0.84 (0.59, 1.20)                           | 0.89 (0.62, 1.28)                           | 0.89 (0.62, 1.28)                           | .32     |
| Chromophobe             | 0.38 (0.19, 0.76)                           | 0.47 (0.23, 0.98)                           | 0.51 (0.25, 1.06)                           | 0.51 (0.25, 1.06)                           | .06     |
| Others                  | 4.69 (3.97, 5.53)                           | 2.15 (1.64, 2.83)                           | 1.74 (1.32, 2.30)                           | 1.74 (1.32, 2.30)                           | <.001   |
| High grade              | 2.52 (2.03, 3.13)                           | 2.43 (1.95, 3.03)                           | <.001                                      | 2.43 (1.95, 3.03)                           | <.001   |
| Late stage              | 4.30 (3.33, 5.54)                           | 3.62 (2.77, 4.74)                           | <.001                                      | 3.62 (2.77, 4.74)                           | <.001   |
| Any surgery             |                                               |                                               |                                             |                                               | .27     |
| High SES                |                                               |                                               |                                             |                                               | .07     |
| Ever smoker             |                                               |                                               |                                             |                                               | .91     |

Abbreviation: SES, socioeconomic status.

1Data were estimated with 20 imputed data sets.

### TABLE 4 Sensitivity analyses for sex differences in renal cell carcinoma histology and survival by Poisson regression with robust variance and Cox proportional hazard model

| Prevalence Ratio (95% Confidence Interval) | All Patients (n = 7525)a | P       | Complete Case (n = 790)b | P       |
|-------------------------------------------|-------------------------|---------|-------------------------|---------|
| Clear cell                                |                         |         |                         |         |
| Women                                     | 0.97 (0.94, 1.01)       | .12     | 0.97 (0.92, 1.02)       | .29     |
| Papillary                                 | 0.67 (0.46, 0.99)       | .04     | 0.74 (0.31, 1.74)       | .48     |
| Chromophobe                               | 3.12 (2.01, 4.87)       | <.001   | 3.46 (1.49, 8.00)       | .004    |
| Others                                    | 1.07 (0.84, 1.37)       | .57     | 1.19 (0.33, 4.35)       | .79     |
| Hazard ratio (95% confidence interval)    |                         |         |                         |         |
| Women                                     | 1.11 (0.99, 1.24)       | .08     | 1.30 (0.74, 2.25)       | .36     |

4Data were estimated with 20 imputed data sets. The numbers of missing data were, respectively, as follows: histological subtypes (2260, 30%), pathological grade (4156, 55%), stage (3296, 44%), surgery (1481, 20%), socioeconomic status (7113, 94%), and smoking habits (5569, 74%). Adjusted for age, year of diagnosis, pathological grade, and smoking habits.

4Adjusted for age, year of diagnosis, pathological grade, stage, socioeconomic status, and smoking habits.

4Data were estimated with 20 imputed data sets. Adjusted for age, year of diagnosis, histological subtype, pathological grade, stage, treatment, socioeconomic status, and smoking habits.

4Adjusted for age, year of diagnosis, histological subtype, pathological grade, stage, treatment, and smoking habits.
The sex difference in the other RCC histological subtypes may be consistent with the data from Western countries. In the Western settings, previous studies suggested that the papillary subtype was less prevalent (OR approximately 0.5 to 0.6) but that the chromophobe subtype was more prevalent (OR 2.3) among women compared with men. In our population-based study in Japan, we confirmed this pattern with similar magnitudes and directions (PRs for papillary and chromophobe subtypes were, respectively, 0.63 and 3.18). Some biological mechanisms, eg, androgen receptor expression, may play a role. Yet, this sex difference is not well-characterized via biological pathways. In addition, the prevalence of the papillary (4.1%) and chromophobe (2.5%) subtypes in the total analyzed population, which parallels the statistics of the Japanese Urological Association, is likely at the lower end of published estimates compared with data from previous studies, suggesting regional disparity in RCC histology.

Regarding sex disparities in RCC survival, women have been previously reported to have better prognosis compared with men, which we did not observe in the present study. In the Western settings, better prognostic factors, including smaller tumor size, low pathological grade, and early stage, are likely more prevalent among women compared with men. However, in this non-Western setting, we did not observe a sex difference in grade/stage. Similarly, a sex difference for grade/stage/tumor size was not found in South Korea. The similar distributions of better prognostic factors between men and women might partly underlie the observed absence of sex disparity in RCC survival in our study, as opposed to studies in the Western setting.

Several limitations in this study should be noted. First, although our data set was population-based, it only represents approximately 7% of the Japanese population in one geographic region, and our obtained pathology diagnoses were not based on a central pathology review. In addition, other relevant outcomes (eg, relative survival) were not evaluated, and complete data were limited for histology and other prognostic variables (including stage) because of missing data, thereby limiting internal and external generalizability. However, our sensitivity analyses with multiple imputation and complete data yielded almost identical results. Second, although we assessed SES and smoking habits, we could not assess other potential predicting factors such as metabolic disorders (eg, obesity, hypertension, and diabetes), tumor size, or performance status, as seen in previous studies. However, hypertension and diabetes did not affect prognosis in a previous study in South Korea. Third, because of the limitation of the data, we were not able to classify histological subtypes further (such as type 1 and type 2 papillary RCC). Since patients with type 2 papillary RCC tend to have poorer prognosis, future studies focusing on sex differences in papillary RCC subtypes are needed.

Despite these limitations, the strengths of our study included the size, as this is one of the most extensive studies conducted for evaluating sex differences in RCC histology in the non-Western setting. Our distribution of the clear cell subtype (88.2%) estimated with population-based data was similar to the SEER data, suggesting our reduced bias compared with nonpopulation-based studies. In addition, while previous population-based studies did not include SES or smoking habits, we were able to take account of these characteristics in our study.

Lastly, RCC patients with the “others” subtype tend to have a poorer prognosis compared with those with the clear cell subtype, and we confirmed this disparity in Japan. In contrast to good prognoses in clear cell, papillary, and chromophobe subtypes (even though survivals tend to differ slightly among the three subtypes), prognosis of the “others” subtype remains poor, with aggressive pathological features (eg, approximately 50% of RCC patients having the “others” subtype tend to present with metastasis). Hence, further studies exploring effects of standard and novel agents for this high-risk population are warranted.

In conclusion, sex differences in RCC histology (papillary and chromophobe subtypes but not clear cell and other subtypes) appear to exist in Japan, which differs from the pattern previously described in Western countries. Sex differences in RCC histology may not affect RCC survival in this population. Further understanding of RCC etiology from an integrated perspective of social and clinicopathological epidemiology may elucidate the determinants of sex differences in RCC histology and prognosis.

**FUNDING**
This work received funding from the Ministry of Health, Labour and Welfare (Industrial Disease Clinical Research Grants 170201-01) and Japan Society for the Promotion of Science (JSPS KAKENHI JP18K17351). The supporting source had no involvement in study design; collection, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication.

**CONFLICT OF INTEREST**
The authors declare no potential conflicts of interest.

**AUTHOR CONTRIBUTIONS**
Conceptualization: Masayoshi Zaitsu, Ichiro Kawachi
Formal Analysis: Masayoshi Zaitsu
Funding acquisition: Masayoshi Zaitsu, Yasuki Kobayashi
Methodology: Masayoshi Zaitsu, Satoshi Toyokawa
Study Supervision: Masayoshi Zaitsu, Yasuki Kobayashi, Ichiro Kawachi
Writing – Original Draft Preparation: Masayoshi Zaitsu
Writing – Review & Editing: Masayoshi Zaitsu, Satoshi Toyokawa, Takumi Takeuchi, Yasuki Kobayashi, Ichiro Kawachi

All authors have read and approved the final version of the manuscript. Masayoshi Zaitsu had full access to all of the data in this study and takes complete responsibility for the integrity of the data and the accuracy of the data analysis.

**TRANSPARENCY STATEMENT**
Masayoshi Zaitsu affirms that this manuscript is an honest, accurate, and transparent account of the study being reported, that no important aspects of the study have been omitted, and that any
discrepancies from the study as planned (and, if relevant, registered) have been explained.

**DATA AVAILABILITY STATEMENT**

The data that support the findings of this study are available from the Kanagawa Cancer Registry. Restrictions apply to the availability of these data, which were used under license for this study by the Kanagawa Cancer Registry; research data used in the study cannot be made publicly available directly by the authors. If any person wishes to verify our data analysis, they are most welcome to contact the corresponding author.

**ORCID**

Masayoshi Zaitsu https://orcid.org/0000-0001-7616-355X

**REFERENCES**

1. Capitanio U, Bensalah K, Box A, et al. Epidemiology of renal cell carcinoma. *Eur Urol*. 2019;75(1):74-84.
2. Znaor A, Lortet-Tieulent J, Laversanne M, Jemal A, Bray F. International variations and trends in renal cell carcinoma incidence and mortality. *Eur Urol*. 2015;67(3):519-530.
3. Zaitsu M, Cuevas AG, Trudel-Fitzgerald C, Takeuchi T, Kobayashi Y, Kawachi I. Occupational class and risk of renal cell cancer. *Health Sci Rep*. 2018;1(6):e49. https://doi.org/10.1002/hsr2.49
4. Zaitsu M, Kaneko R, Takeuchi T, Sato Y, Kobayashi Y, Kawachi I. Occupational inequalities in female cancer incidence in Japan: hospital-based matched case-control study with occupational class. *SSM Popul Health*. 2018;5:129-137.
5. Zaitsu M, Kaneko R, Takeuchi T, Sato Y, Kobayashi Y, Kawachi I. Occupational class and male cancer incidence: nationwide, multicenter, hospital-based case-control study in Japan. *Cancer Med*. 2019;8(2):795-813.
6. Rothman J, Egleston B, Wong YN, Iffrig K, Lebovitch S, Uzzo RG. Histopathological characteristics of localized renal cell carcinoma correlate with tumor size: a SEER analysis. *J Urol*. 2009;181(1):29-33. discussion 33-4
7. Capitanio U, Cloutier V, Zini L, et al. A critical assessment of the prognostic value of clear cell, papillary and chromophobe histological subtypes in renal cell carcinoma: a population-based study. *BJU Int*. 2009;103(11):1496-1500.
8. Keegan KA, Schupp CW, Chapin K, Hellinghal NJ, Evans CP, Koppie TM. Histopathology of surgically treated renal cell carcinoma: survival differences by subtype and stage. *J Urol*. 2012;188(2):391-397.
9. Teloken PE, Thompson RH, Tickoo SK, et al. Prognostic impact of histological subtype on surgically treated localized renal cell carcinoma. *J Urol*. 2009;182(5):2123-2136.
10. Leibovich BC, Lohse CM, Crispin PL, et al. Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. *J Urol*. 2010;183(4):1309-1315.
11. Aron M, Nguyen MM, Stein RJ, Gill IS. Impact of gender in renal cell carcinoma: an analysis of the SEER database. *Eur Urol*. 2008;54(1):133-140.
12. Purdue MP, Moore LE, Merino MJ, et al. An investigation of risk factors for renal cell carcinoma by histologic subtype in two case-control studies. *Int J Cancer*. 2013;132(11):2640-2647.
13. Lipworth L, Morgans AK, Edwards TL, et al. Renal cell cancer histological subtype distribution differs by race and sex. *BJU Int*. 2016;117(2):260-265.
14. May M, Aziz A, Zigeuner R, et al. Gender differences in clinicopathological features and survival in surgically treated patients with renal cell carcinoma: an analysis of the multicenter CORONA database. *World J Urol*. 2013;31(5):1073-1080.
15. Callahan CL, Hofmann JN, Corley DA, et al. Obesity and renal cell carcinoma risk by histologic subtype: a nested case-control study and meta-analysis. *Cancer Epidemiol*. 2018;56:31-37.
16. Lovejoy JC, Sainsbury A. Stock Conference 2008 Working Group. Sex differences in obesity and the regulation of energy homeostasis. *Obes Rev*. 2009;10(2):154-167.
17. Patel NH, Attwood KM, Hanzly M, et al. Comparative analysis of smoking as a risk factor among renal cell carcinoma histological subtypes. *J Urol*. 2015;194(3):640-646.
18. Kanayama H, Fukumori T, Fujimoto H, et al. Clinicopathological characteristics and oncological outcomes in patients with renal cell carcinoma registered in 2007: the first large-scale multicenter study from the cancer registration committee of the Japanese Urological Association. *Int J Urol*. 2015;22(9):S1-S7.
19. Lee S, Jeon HG, Kwak C, et al. Gender-specific clinicopathological features and survival in patients with renal cell carcinoma (RCC). *BJU Int*. 2012;110(2 Pt 2):E28-E33.
20. Zaitsu M, Toyokawa S, Toyooka A, et al. Sex differences in bladder cancer pathology and survival: analysis of a population-based cancer registry. *Cancer Med*. 2015;4(3):363-370.
21. Zaitsu M, Kim Y, Lee H-E, Takeuchi T, Kobayashi Y, Kawachi I. Occupational class differences in pancreatic cancer survival: a population-based cancer registry-based study in Japan. *Cancer Med*. 2019;8(6):3261-3268.
22. Chow WH, Shuch B, Linehan WM, Devesa SS. Racial disparity in renal cell carcinoma patient survival according to demographic and clinical characteristics. *Cancer*. 2013;119(2):388-394.
23. Zaitsu M, Kawachi I, Ashida T, Kondo K, Kondo N. Participation in community group activities among older adults: is diversity of group membership associated with better self-rated health? *J Epidemiol*. 2018;28(11):452-457.
24. Kocher NJ, Rjepaj C, Robyak H, Lehman E, Raman JD. Hypertension is the primary component of metabolic syndrome associated with pathologic features of kidney cancer. *World J Urol*. 2017;35(1):67-72.
25. Hitchman SC, Fong GT. Gender empowerment and female-to-male smoking prevalence ratios. *Bull World Health Organ*. 2011;89(3):195-202.
26. Langner C, Ratschek M, Rehak P, Schips L, Zigeuner R. Steroid hormone receptor expression in renal cell carcinoma: an immunohistochemical analysis of 182 tumors. *J Urol*. 2004;171(2 Pt 1):611-614.
27. Beisland C, Medby PC, Beisland HO. Renal cell carcinoma: gender difference in incidental detection and cancer-specific survival. *Scand J Urol Nephrol*. 2002;36(6):414-418.
28. Sunela KL, Kataja MJ, Lehtinen ET, et al. Prognostic factors and long-term survival in renal cell cancer patients. *Scand J Urol Nephrol*. 2009;43(6):454-460.
29. Ito K, Mikami S, Tatsugami K, et al. Clinical outcomes in patients with metastatic papillary renal-cell carcinoma: a multi-institutional study in Japan. *Clin Genitourin Cancer*. 2018;16(6):e1201-e1214.
30. de Velasco G, McKay RR, Lin X, Moreira RB, Simantov R, Choueiri TK. Comprehensive analysis of survival outcomes in non-clear cell renal cell carcinoma patients treated in clinical trials. *Clin Genitourin Cancer*. 2017;15(6):652-660.e1.

How to cite this article: Zaitsu M, Toyokawa S, Takeuchi T, Kobayashi Y, Kawachi I. Sex-specific analysis of renal cell carcinoma histology and survival in Japan: A population-based study 2004 to 2016. *Health Sci Rep*. 2020;3:e142. https://doi.org/10.1002/hsr2.142